Mintz represented long-time client Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, in its $80 million financing from Ginkgo Bioworks, the organism company, and the related collaboration between them. The investment will accelerate expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines, including those developed using Ginkgo’s cell programming platform.
The agreements provide an $80 million equity investment in Synlogic by Ginkgo, made at a premium price, and the parties’ entrance into a long-term strategic platform collaboration. Synlogic will use Ginkgo’s cell programming platform for building and testing thousands of microbial strains to accelerate the progression of early preclinical leads to drug candidates optimized for further clinical development.
Mintz has previously helped Synlogic raise over $200 million in private and public capital, as well as approximately $40 million of capital acquired another $40 million as Synlogic became a public company via reverse merger with Mirna Therapeutics. This most recent transaction was worked on by Lewis Geffen, Matt Gardella, and Dan Bagliebter.